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https://doi.org/10.1002/nbm.4061A better understanding of the coupling between changes in cerebral blood flow (CBF)
and cerebral blood volume (CBV) is vital for furthering our understanding of the
BOLD response. The aim of this study was to measure CBF‐CBV coupling in different
vascular compartments during neural activation. Three haemodynamic parameters
were measured during a visual stimulus. Look‐Locker flow‐sensitive alternating inver-
sion recovery was used to measure changes in CBF and arterial CBV (CBVa) using
sequence parameters optimized for each contrast. Changes in total CBV (CBVtot) were
measured using a gadolinium‐based contrast agent technique. Haemodynamic
changes were extracted from a region of interest based on voxels that were activated
in the CBF experiments. The CBF‐CBVtot coupling constant αtot was measured as
0.16 ± 0.14 and the CBF‐CBVa coupling constant αa was measured as 0.65 ± 0.24.
Using a two‐compartment model of the vasculature (arterial and venous), the change
in venous CBV (CBVv) was predicted for an assumed value of baseline arterial and
venous blood volume. These results will enhance the accuracy and reliability of appli-
cations that rely on models of the BOLD response, such as calibrated BOLD.
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The relationship between changes in cerebral blood flow (CBF) and cerebral blood volume (CBV) is critical for an accurate understanding of the
haemodynamics that underlie blood oxygenation level dependent (BOLD) fMRI, and a greater understanding of cerebral haemodynamics will lead
to more precise quantification of the BOLD response.1,2 Early studies suggested that the majority of CBV change in response to neuronal activation
occurs in venous vessels.3,4 This led to the adoption of a CBF‐CBV coupling model based on a power law relationship that was characterized using
PETmeasurements of CBF and total CBV (CBVtot).
5 However, it is nowwell known that arterial CBV (CBVa) also increases on activation, and that this
occurs to a much greater degree than total CBV, despite the lower baseline CBV of the arterial compartment.6-8 Therefore, the use of a CBF‐CBVtot- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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LD, blood oxygenation level dependent; CASL, continuous arterial spin labelling; CBF, cerebral blood flow; CBV,
; GBCA, gadolinium‐based contrast agent; ITS‐FAIR, inflow turbo‐sampling echo planar imaging flow‐sensitive
sed vascular space occupancy; LL‐EPI, Look‐Locker echo planar imaging; LL‐FAIR, Look‐Locker flow‐sensitive
rial spin labelling; PCASL, pseudocontinuous arterial spin labelling; SENSE, sensitivity encoding; SNR, signal to
C, velocity encoding; VERVE, venous refocusing for volume estimation
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2 of 11 WESOLOWSKI ET AL.coupling constant will overestimate changes in venous CBV (CBVv). This led to measurements of a CBF‐CBVv coupling constant using the CBVv
sensitive venous refocusing for volume estimation (VERVE) technique.9,10 Despite this, the coupling between CBF and CBVa is still poorly
understood in humans, with the majority of research having been performed in rats.6,7 Whilst changes in CBVa are typically invisible in the context
of standard BOLD fMRI, they become significant in studies utilizing intravascular contrast agents11 or hypoxic hypoxia,12 where an arterial signal
change occurs due to the presence of paramagnetic contrast agent or deoxyhaemoglobin, respectively, in the arterial blood volume, the latter having
implications for the application of these methods in cerebrovascular disease, where patients may have a reduced arterial oxygen saturation.
One reason why there is only a small number of published studies examining the relationship between these parameters is the limited number
of techniques for measuring CBVtot, CBVa and CBVv in humans. Fractional changes in CBVtot (ΔCBVtot) during a stimulus have been measured via
an infusion of a gadolinium‐based contrast agent (GBCA).13-15 Such experiments rely on measuring changes in the stimulus evoked BOLD
response as a function of intravascular contrast agent concentration, which can either be increased using an extended infusion, or decreased
by clearance of a bolus of contrast agent via the kidneys.16 This is in contrast to dynamic susceptibility contrast based techniques that are not
generally temporally resolved and are more commonly used to measure absolute resting CBVtot. Vascular space occupancy (VASO) has also been
shown to provide a method for the assessment of total CBV.17 However, it is not possible to measure ΔCBVtot using VASO without prior knowl-
edge of the baseline CBVtot, thus making this technique unsuitable for the study of CBF‐CBVtot coupling. Arterial spin labelling (ASL)‐based
approaches have emerged for the measurement of CBVa; these include inflow‐based VASO (iVASO)
18 and Look‐Locker flow‐sensitive alternating
inversion recovery (LL‐FAIR).8 LL‐FAIR combines the FAIR ASL technique with Look‐Locker echo planar imaging (LL‐EPI) sampling19 to sensitize
the signal to either CBF using vascular crushing20 or CBVa,
8 depending on the sequence parameters. This technique is also presented in the liter-
ature as ITS‐FAIR (inflow turbo‐sampling EPI flow‐sensitive alternating inversion recovery)21 and QUASAR (quantitative signal targeting with alter-
nating radio frequency labelling of arterial regions),22 the latter requiring the subtraction of scans with and without vascular crushing to estimate
CBVa. Since the LL‐FAIR technique is also capable of measuring transit time of labelled blood, it is also able to account for changes in transit time
that may occur during neuronal activation. LL‐FAIR also has a higher signal to noise ratio (SNR) per unit time for measurement of perfusion than
conventional FAIR.21 CBVv measurements have been made using the VERVE technique
23 or hyperoxia BOLD contrast24 methods. However,
VERVE is hampered by assumptions regarding oxygenation changes during activation and hyperoxia BOLD contrast by relatively low SNR.
In this study, LL‐FAIR‐based measurements of CBF and CBVa are acquired alongside estimates of ΔCBVtot using a GBCA technique. The rela-
tionship between the resultant haemodynamic parameters is assessed using a power law relationship, building upon early studies of CBF‐CBV
coupling,5 the calibrated BOLD method1,2 and BOLD modelling studies.3,4 This analysis yields CBF‐CBVa and CBF‐CBVtot coupling constants.
These measurements are also used to predict the change in CBVv for an assumed arterial and venous volume fraction.2 | THEORY
2.1 | LL‐FAIR for measurement of CBF
LL‐FAIR combines a FAIR ASL labelling scheme with LL‐EPI sampling. The sequence can be sensitized to CBF by using an initial inversion delay (TI)
to allow inflowing blood to arrive at the imaging plane (TI = 600 ms) followed by low flip angle pulses (θ = 35°) for the EPI readouts with a time
interval (TA = 350 ms) such that the perfusion signal is not fully suppressed and can be sampled multiple times Figure 1B). Vascular crushing is
added to minimize any CBVa signal contribution from the macrovasculature.
CBF is then quantified by iteratively modelling the signal due to multiple readout pulses using a kinetic model that takes into account the dura-
tion of the labelled blood arriving in the tissue, the effect of the readout pulse on both arterial blood magnetization and tissue magnetization, and
incomplete blood magnetization recovery at short repetition times. This is performed by solving a three‐compartment model, where Compartment
1 contains arterial blood located outside of the imaging volume, Compartment 2 contains arterial blood inside the imaging volume and Compart-
ment 3 contains blood in the capillary bed, which is in exchange with the tissue. For a complete description see Reference 20.
2.2 | LL‐FAIR for measurement of CBVa
Alternatively, the LL‐FAIR scheme can be sensitized to CBVa. This is performed by using an LL‐FAIR scheme with a short initial delay (TI = 150 ms)
and closely spaced (TA = 100 ms) high flip angle pulses (θ = 50°) for the EPI readout, which are acquired at the shortest achievable echo time
(Figure 1C). This has the advantage of providing a large number of EPI readout time points of high SNR to well sample the arterial blood volume
inflow curve for quantification of CBVa,
8 whilst suppressing any CBF contribution.20 CBVa is quantified by iteratively modelling the signal across
the readout pulses in the arterial blood compartment (Compartment 2 described above) using a kinetic model.8
2.3 | Gadolinium infusion for measurement of CBVtot
By infusing a contrast agent during an fMRI paradigm whilst acquiring dual‐echo BOLD weighted images for estimation of the transverse relaxation
rate (R2*), the signal can be sensitized to changes in CBVtot. Quantification of this signal is achieved by comparing measurements of R2* at rest and
FIGURE 1 A, overview of the experimental protocol including visual stimulus blocks (red lines), contrast agent injections (arrow Gd) and
experimental details. B, example pulse sequence diagram of LL‐FAIR scheme used for CBF quantification with FAIR labelling followed by five
EPI readouts. The initial four flip angles have θ = 35°, with a final readout pulse of flip angle of 90°. The first readout pulse occurs following an
initial inversion delay (TI = 600 ms) with subsequent readouts separated by a time interval (TA = 350 ms). Data are collected with vascular crushing
(VENC = 7.8 mm/s). the sequence is then repeated with repetition timeTR. C, CBVa quantification with FAIR labelling followed by 19 EPI readouts.
The first 18 flip angles are θ = 50°, with a final readout pulse of flip angle of 90°. The first readout pulse occurs following an initial inversion delay
(TI = 150 ms), with subsequent readouts separated by a time interval (TA = 100 ms). The sequence is then repeated with repetition time TR
WESOLOWSKI ET AL. 3 of 11during activation.13-15 Under the assumption that stimulus evoked changes in R2* are constant across multiple trials, additional contributions to R2*
across trials are expected to be solely due to the contrast agent in the blood. In addition, it is assumed that the effect of the contrast agent on the
measured signal is predominantly extravascular in origin. Therefore, during rest the measured change in R2* due to contrast agent can bemodelled as
ΔR*rest2 ¼ κ Vtot CA½  χCA; (1)
where κ is a constant representing physical properties of the experiment, Vtot is the resting CBVtot, [CA] is the contrast agent concentration in the
blood and χCA is the molar magnetic susceptibility of the contrast agent.
11 During the active condition, the measured change in R2* due to contrast
agent is
ΔR*act2 ¼ κ Vtot þ ΔVtotð Þ CA½  χCA; (2)
whereΔVtot is the resultant change in CBVtot. Therefore, the fractional change in CBVtot (δCBVtot) can be estimated by taking the ratio of Equation 1
and Equation 2.
ΔR*act2
ΔR*rest2
¼ ΔVtot
Vtot
þ 1 ¼ δCBVtot þ 1: (3)
In an idealized experiment the fMRI stimulus paradigm would be repeated twice, first in the absence of contrast agent and second during a
steady state concentration of contrast. However, in practice this is not feasible in human subjects due to dosage limits of GBCAs and their rapid
elimination. Therefore, here R2* measurements are made in the presence of a slowly changing contrast agent concentration provided by an
infusion of a GBCA, with ΔR*rest2 being extrapolated from periods of rest during activated time points.
153 | METHODS
3.1 | Imaging
This study was approved by the University of Nottingham Medical School Ethics Committee. Eight healthy volunteers aged 20 to 31 years
(24 ± 3 years, mean ± standard deviation) gave written consent and were scanned as part of this study. A schematic diagram of the experimental
protocol is given in Figure 1a. Subjects were cannulated prior to entering the scanner to provide access for the injection of contrast agent and
ensure that any motion during the Gd injection in the CBVtot experiment was minimal.
4 of 11 WESOLOWSKI ET AL.Data were acquired on a Philips Achieva 3 T system (Philips Healthcare, Best, The Netherlands), using a body transmit coil and eight‐channel
SENSE (sensitivity encoding) head receive coil. All three haemodynamic parameter measurements were acquired with a common spatial resolution
of 3 × 3 × 5 mm3, matrix size of 64 × 64 and SENSE factor 2 and matched bandwidth. Measurements of CBF and CBVa were limited to a single
slice acquisition at the time these experiments were performed. Therefore, an initial functional localizer scan was performed in order to select a
single axial slice through the visual cortex with the largest region of BOLD activation. This slice prescription was then used throughout the rest of
the experiment.
Visual stimulation was provided by red LED goggles flashing at 8 Hz. Lights were on for 19.2 s and off for the remainder of the 60 s cycle. The
number of stimulus cycles varied reflecting the differing SNR of each method: eight cycles were collected for CBVa measurements, 12 cycles for
CBF (which has a lower contrast to noise ratio) and 14 cycles for CBVtot.
An LL‐FAIR acquisition was used to allow the assessment of both CBF and CBVa measurements accounting for transit time effects. The com-
bination of a Look‐Locker acquisition with a FAIR preparation enables the tagged bolus to be tracked through the macrovascular system and into
the tissue sensitizing the signal to CBVa or CBF by using the appropriate combination of sequence parameters. In both cases the thickness of the
inversion slab was alternated between 30 mm and 200 mm for label and control conditions, respectively. The sequence parameters for the CBF
measurement comprised an initial inversion delayTI = 600 ms, time interval between EPI readoutsTA = 350 ms (resulting in an inversion time range
of 600 ms to 2000 ms), flip angle θ = 35° and five readout pulses with vascular crushing (bipolar lobe of 5 ms duration per lobe and amplitude of
15 mT, velocity encoding (VENC) = 7.8 mm/s). For the CBVa measurement, the sequence comprised TI = 150 ms, TA = 100 ms (resulting in an
inversion time range of 150 ms to 1950 ms), θ = 50°, with 19 readout pulses. In both CBF and CBVa measurements the shortest achievable echo
time of 16 ms was used and the final LL‐FAIR pulse had a flip angle of 90° to maximize SNR. The LL‐FAIR scheme was performed with in‐plane
pre‐ and post‐saturation pulses to provide signal suppression of the imaging slice, thus reducing any offset signals due to imperfections between
the selective and non‐selective RF inversion pulses. The application of a 90° pulse at the end of eachTR simplified the modelling, as it ensured that
each tag/control acquisition is independent, removing the need for an iterative fit of the data to be performed. The TR between inversion pulses
was 2.4 s, resulting in a label/control pair being collected every 4.8 s.
For the measurement of CBVtot, dual‐echo GE‐EPI images were acquired with TE = 13/35 ms, TR = 1.2 s and three slices. Two single doses
(0.2 mL kg−1) of Gadoteridol (ProHance, Bracco Imaging, Milan, Italy) were injected, the first bolus at the beginning of the fifth stimulus cycle
and the second at the beginning of the sixth cycle. For Cycles 5 and 6, the visual stimulus was not presented and data from these cycles were
not used in the estimation of ΔCBVtot. The final 10 cycles of the visual stimulus, after contrast agent injection, were acquired at different contrast
agent concentration levels during clearance of the contrast by the kidneys.3.2 | Analysis
For each subject, CBF, CBVa and CBVtot data sets were first realigned within each data set and then across all data sets using SPM5 (5 mm FWHM
Gaussian smoothing kernel and second degree B‐spline interpolation).25 Since the CBF and CBVa data were acquired for a single slice, motion cor-
rection was restricted to in‐plane motion and rotation. In the case of the CBVtot measurement, the acquisition of three slices provided for the cor-
rection of small amounts of through‐slice motion. For the CBF and CBVa data, the images from the final LL‐FAIR readout pulse (90° flip angle and
thus highest SNR) of each volume acquisition (TR period) were realigned, and this transformation matrix then applied to the images acquired from
the other LL readout pulses within the corresponding TR period. The CBVtot datasets were realigned using the images acquired at the first echo,
and this transformation matrix was then applied to the second echo data. Data for each echo time was then down‐sampled to produce a complete
time series with a 2.4 s temporal resolution (matching the CBF and CBVa datasets), and only a single slice co‐registered to the CBF and CBVa
datasets was retained.
For the CBF and CBVa data, difference images were first computed from the subtraction of consecutive label and control pairs to provide a
time series of CBF‐ and CBVa‐weighted images for each LL‐readout pulse. Average CBF‐ and CBVa‐weighted time series during the visual stimulus
cycle were then formed by averaging across cycles, accounting for jittering in the data relative to the stimulus paradigm (thus generating a CBF‐
weighted and CBVa‐weighted time series of LL readouts for each time point per stimulus cycle). CBVa‐weighted difference images were quantified
to estimate arterial transit time and CBVa voxelwise using a two‐parameter fit, as described in Reference 8, over an averaged stimulus cycle. CBF‐
weighted difference images were initially analysed using a two‐parameter fit for capillary transit time and CBF.20 However, since the data had
lower SNR than the CBVa data, a two‐parameter fit for each time point within the stimulus cycle was found to increase the noise in the measure-
ment of CBF. Therefore, a mean estimate of the transit time at baseline and on activation was computed and used in a one‐parameter model fit to
produce a voxelwise estimates of CBF at each time point over an averaged stimulus cycle.
For the CBVtot data, time series of R2* values were calculated for each voxel using the realigned, down‐sampled, dual echo data. The
fractional change in CBVtot (δCBVtot) was calculated by considering the effect of the contrast agent on the R2* (transverse relaxation rate) changes
that occur during the BOLD response, as shown previously by using an infusion to gradually increase the contrast agent concentration.15
However, in this study two bolus injections of contrast agent were used to raise the initial blood contrast agent concentration, which gradually
decreased due to washout through the kidneys. In the analysis, four stimulus cycles prior to the contrast agent injections provided a baseline.
Stimulus cycles following immediately after the injections were discarded to allow for recirculation of the contrast agent, leaving the final nine
WESOLOWSKI ET AL. 5 of 11cycles for analysis. In all other aspects, this method is the same as in previous reports, and resulted in an estimate of ΔCBVtot over an averaged
stimulus cycle.11,15
Activated regions were generated for each subject using a correlation analysis of the stimulus delivery applied to the quantified CBF maps in
order to be maximally sensitive to the site of activation. Each CBF region of interest (ROICBF) was defined based on the CBF statistical map thresh-
old at p < 0.01 (uncorrected). In addition, a supplementary analysis was performed to examine the impact of a different ROI definition based on
common activated voxels across the three measures of CBVa, CBF and δCBVtot. Statistical maps from each measure were thresholded at p < 0.01
(uncorrected) and voxels at the intersection retained to form a common ROI (ROICOMMON).
3.3 | Estimation of CBF‐CBV coupling
The coupling between CBF and CBV during neuronal activation was calculated assuming a power law relationship between CBF and CBVtot,
CBVtot ¼ ζ CBFαtot ; (4)FIGURE 2 Example LL‐FAIR difference images from a single subject as a function of post‐label delay time averaged over all experimental time
points. A, CBF‐weighted images were acquired using five EPI readouts with the first four flip angles of θ = 35° and a final excitation pulse of
θ = 90°. B, CBVa‐weighted images were acquired using 19 EPI readouts with flip angles of θ = 50° and a final excitation pulse of θ = 90°
6 of 11 WESOLOWSKI ET AL.where values of ζ and αtot have previously been measured in rhesus monkeys using a hyper/hypocapnia challenge as 0.80 and 0.38, respectively.
5
Given measurements of the fractional change (i.e. the absolute change in CBV divided by absolute baseline CBV) in CBVtot (δCBVtot) and CBF
(δCBF) in response to the visual stimulus, which is dimensionless, the CBF‐CBVtot coupling constant αtot (Grubb's constant) can be estimated
by rearranging Equation 4:
αtot ¼ ln δCBVtot þ 1ð Þln δCBFþ 1ð Þ : (5)
Under the assumption that the relationship between CBF and CBVa can be described by the power law relationship given in Equation 4, a
CBF‐CBVa coupling constant αa can be defined. In this case δCBVa is the fractional change in CBVa, which is also dimensionless.
αa ¼ ln δCBVa þ 1ð Þln δCBFþ 1ð Þ: (6)
Using these equations, Grubb's constant, αtot, and the CBF‐CBVa coupling constant, αa, were estimated on a per subject basis. Values for
δCBF, δCBVtot and δCBVa were extracted from the quantified maps of each parameter and averaged over each of the ROIs. The time window
for the active on condition was defined as between 9.6 s and 19.2 s from the start of the stimulus cycle, whilst the baseline off condition was
defined to be between 40.8 s and 60 s. Estimates of αtot and αa were then computed using Equations 5 and 6, respectively.
In the absence of direct measurements of CBVv, we estimated the fractional change in venous CBV (δCBVv) using a simple model of the vas-
cular compartments. Changes in total blood volume were approximated as a volume‐weighted sum of two compartments: arterial and venous,
δCBVtot ¼ fa δCBVa þ fvδCBVv; (7)FIGURE 3 Example time courses of the raw
signal for each modality from a single subject
averaged over the CBF‐based region of
interest. A, CBVa‐weighted LL‐FAIR
difference data were acquired over eight
stimulus cycles. B, CBF‐weighted LL‐FAIR
difference data were acquired over 12
stimulus cycles. C, CBVtot‐weighted gradient
echo (GE) EPI data were acquired over a
period of 16 min. Two single‐dose boluses of
a GBCA were injected at the beginning of
minutes 4 and 5. The visual stimulus was
presented for the remaining cycles
WESOLOWSKI ET AL. 7 of 11where f a and f v are the volume fractions assigned to arterial and venous blood volume compartments ( f a = CBVa/CBVtot, f v = CBVv/CBVtot),
respectively, and here it is assumed that f a + f v = 1. The capillary volume is assumed to be distributed between the arterial and venous compart-
ments. By rearranging Equation 7, δCBVv can be predicted as a function of arterial and venous volume fractions f a and f v:
δCBVv ¼ δCBVtot − faδCBVafv : (8)
4 | RESULTS
Figures 2 and 3 show examples of the raw data acquired in this study from a single subject. The former shows CBF‐weighted (Figure 2A) and
CBVa‐weighted (Figure 2B) LL‐FAIR difference images as a function of post‐label delay time averaged over all experimental timepoints; note
the higher CNR of the CBVa‐weighted data. The latter presents time courses of CBVa‐, CBF‐ and CBVtot‐weighted data averaged over the voxels
in the ROICBF (Figure 3). For this, CBF weighting was achieved by averaging across three LL readouts with post‐label delay times of 950, 1300 and
1650 ms. Similarly, CBVa weighting was obtained by averaging across eight LL readouts with post‐label delay times of 350, 450, 550, 650, 750,
850, 950 and 1050 ms. Finally, the CBVtot‐weighted time course was generated using the second echo of the GE‐EPI dataset (TE = 35 ms).
Estimates of the mean transit time for CBF‐weighted (perfusion transit time) and CBVa‐weighted (arterial transit time) data are presented in
Table 1. These data were extracted from the CBF‐based ROI of each subject. During activation the perfusion transit time was found to be signif-
icantly reduced (p < 0.05, paired two‐tailed t‐test), but the change in the arterial transit time was not significant (p = 0.11).
Figure 4 displays the time course for the dimensionless fractional change in each haemodynamicmeasure (δCBVa, δCBF and δCBVtot) per subject
(grey lines), and the group mean weighted by the number of voxels in each subject's CBF derived ROI (solid black line) (seeTable 1). Table 2 provides
the fractional change measured for each haemodynamic parameter for ROICBF, along with the predicted value of δCBVv estimated assuming a value
of arterial volume fraction of f a = 0.3 ( f v = 0.7) (this choice of value is discussed below). The uncertainty in each parameter was estimated as the
standard deviation of the voxels in the ROI for the measured parameters (baseline and changes in CBVa, CBF and CBVtot) and propagated from these
values for the calculated parameters (δCBVv, αtot and αa). Measurements of δCBVtot and δCBVa were found to be statistically significantly different
from zero across the group (one‐sample t‐test, p < 0.05), with estimates of αtot and αa provided in Table 2 for each subject and group means of
0.16 ± 0.14 and 0.65 ± 0.24, respectively. In contrast, the estimated value of δCBVv was not statistically significantly different from zero
(p = 0.33), which would suggest a CBF‐CBVv coupling constant, αv, of close to zero. Quantified baseline estimates of CBF and CBVa from the baseline
timewindow are also presented inTable 2. Baseline CBVa was found to be inversely correlatedwith δCBVa (correlation coefficient, R = −0.68). Group
means and standard deviations inTable 2 areweighted by the number of voxels in each subject's ROI. The number of voxels included in the ROI varied
across subjects, probably due to the use of single‐slice techniques, and in some subjects sub‐optimal placement of the slice. It should be noted that,
whilst measurements of δCBVtot have the lowest group standard deviation, when coupled with a low mean value of δCBVtot this technique has the
highest relative standard deviation. This propagates through to greater uncertainty in the value of αtot compared with αa.
The results of the supplementary analysis using a common ROI are presented in the Supporting Information. Figure S1 parallels Figure 4,
displaying the fractional changes in each of the haemodynamic measures for the common ROI. However, it should be noted that by producing
the ROICOMMON as the intersection of changes in CBVa, CBF and CBVtot the number of included voxels is low across all subjects and zero for
one subject (Table S1). Despite this, larger changes in all haemodynamic parameters were observed compared with the results from ROICBF,
and a significant increase in CBVv was detected (one‐sample t‐test, p < 0.05). This enabled αv to be estimated as 0.29 ± 0.15 across the group,
alongside values of 0.45 ± 0.14 for αtot and 0.70 ± 0.29 for αa. These results can be found in Table S2.TABLE 1 Data extracted from ROICBF. Experimental measurements of the mean CBF‐weighted (perfusion) and CBVa‐weighted (arterial) transit
times. Per subject standard deviations are presented along with the group mean and standard deviation of each parameter weighted by the
number of voxels in each subject's ROI
Subject no No of voxels
Perfusion transit time Arterial transit time
On Off On Off
1 22 0.73 ± 0.04 0.72 ± 0.10 0.23 ± 0.08 0.24 ± 0.09
2 41 0.56 ± 0.05 0.66 ± 0.08 0.18 ± 0.01 0.21 ± 0.01
3 80 0.44 ± 0.03 0.61 ± 0.05 0.38 ± 0.01 0.54 ± 0.06
4 5 0.55 ± 0.13 0.46 ± 0.13 0.12 ± 0.02 0.16 ± 0.12
5 70 0.58 ± 0.04 0.80 ± 0.17 0.16 ± 0.01 0.13 ± 0.02
6 107 0.64 ± 0.02 0.67 ± 0.04 0.29 ± 0.02 0.24 ± 0.02
7 77 0.46 ± 0.04 0.66 ± 0.04 0.26 ± 0.01 0.38 ± 0.03
8 13 0.78 ± 0.06 0.93 ± 0.08 0.51 ± 0.06 0.63 ± 0.06
Weighted mean & st. dev. 0.56 ± 0.10 0.68 ± 0.08 0.27 ± 0.08 0.31 ± 0.15
FIGURE 4 Haemodynamic changes during visual stimulation extracted from an ROI defined based on changes in CBF in response to the
stimulus: Fractional change in arterial CBV (δCBVa) (a), fractional change in CBF (δCBF) (B) and fractional change in total CBV (δCBVtot) (C).
time courses are displayed for all subjects (grey lines) and group mean weighted by the number of voxels in each subject's ROI (black solid line).
The visual stimulus period is denoted by a solid black bar and averaging windows highlighted for on (pink; 9.6–19.2 s) and off (blue; 40.8–60 s)
conditions
TABLE 2 Data extracted from ROICBF. Experimental measurements of baseline CBF in mL/100 g/min and arterial CBV (CBVa) in mL/100 g are
presented alongside dimensionless steady state fractional changes in CBF (δCBF), CBVa (δCBVa) and CBVtot (δCBVtot), as well as values of δCBVv
estimated assuming a value of arterial volume fraction f a = 0.3 ( f v = 0.7). Values of the exponents αtot and αa are calculated on a per subject basis.
Per subject standard deviations are presented along with the group mean and standard deviation of each parameter weighted by the number of
voxels in each subject's ROI
Subject No of voxels CBF δCBF δCBVtot CBVa δCBVa δCBVv αtot αa
1 22 101.7 ± 6.9 0.22 ± 0.16 0 ± 0.03 4.12 ± 0.04 0.06 ± 0.02 −0.03 ± 0.04 −0.02 ± 0.13 0.31 ± 0.20
2 41 66.9 ± 4.9 0.39 ± 0.14 0.06 ± 0.03 4.51 ± 0.03 0.15 ± 0.05 0.02 ± 0.05 0.18 ± 0.10 0.43 ± 0.13
3 80 66.9 ± 2.3 0.37 ± 0.07 0.07 ± 0.02 0.94 ± 0.02 0.26 ± 0.04 −0.02 ± 0.03 0.20 ± 0.06 0.72 ± 0.12
4 5 54.5 ± 4.2 0.63 ± 0.18 0.22 ± 0.04 0.69 ± 0.02 0.77 ± 0.08 −0.02 ± 0.06 0.41 ± 0.11 1.18 ± 0.28
5 70 47.3 ± 11.7 0.49 ± 0.52 −0.01 ± 0.07 1.48 ± 0.19 0.21 ± 0.16 −0.10 ± 0.12 −0.02 ± 0.17 0.47 ± 0.41
6 107 53.3 ± 10.2 0.67 ± 0.28 0.04 ± 0.05 0.79 ± 0.03 0.61 ± 0.07 −0.20 ± 0.08 0.08 ± 0.10 0.94 ± 0.31
7 77 60.1 ± 10.2 0.41 ± 0.09 0.13 ± 0.04 1.76 ± 0.02 0.16 ± 0.03 0.12 ± 0.06 0.37 ± 0.13 0.42 ± 0.07
8 13 73.7 ± 4.4 0.63 ± 0.12 0.19 ± 0.10 0.83 ± 0.04 0.75 ± 0.11 −0.05 ± 0.15 0.36 ± 0.18 1.15 ± 0.17
Weighted mean & st. dev. 60.7 ± 12.3 0.48 ± 0.13 0.06 ± 0.05 1.37 ± 0.75 0.32 ± 0.21 −0.05 ± 0.11 0.16 ± 0.14 0.65 ± 0.24
8 of 11 WESOLOWSKI ET AL.Details of how to access the data underpinning the results presented in this study can be found in the appendix.5 | DISCUSSION
A good understanding of the relationship between changes in CBF and CBV is important for interpreting the physiological changes that underlie func-
tional hyperaemia. However, how these changes translate to a measured BOLD response depends on how such changes are distributed across the dif-
ferent vascular compartments. The results of this studywill help to improvemodels of the BOLD response.11,26 In turn this will enhance the accuracy and
reliability of applications that rely on a correct understanding of the BOLD response. For example, it has been shown that the accuracy of the calibrated
BOLD method for quantifying stimulus evoked oxygen metabolism changes is critically dependent on accurate knowledge of CBF‐CBVv coupling.
26,27
In this study, measurements of CBF, CBVa and CBVtot were combined to assess the coupling of CBF changes with changes in arterial, venous
and total CBV, within two functionally defined ROIs. For the CBF derived ROI, the CBF‐CBVtot coupling constant αtot was estimated to be
0.16 ± 0.14 and the CBF‐CBVa coupling constant αa was estimated to be 0.65 ± 0.24 (mean ± standard deviation). The estimated change in CBVv
within this ROI was not statistically significant. Supplementary analysis using a common ROI (ROICOMMON) provided contrasting results, which are
discussed later in this section.5.1 | Comparison with the literature
The coupling between CBF and CBVtot has been the target of numerous studies. The power law relationship (Equation 1) was first introduced by
Grubb et al, who measured αtot to be 0.38 in anaesthetized rhesus monkeys during steady state hyper/hypocapnic challenges.
5 Further PET mea-
surements in humans, using a combination of radiolabelled water (H2
15O) and carbon monoxide (C15O or 11CO), measured αtot to be 0.3 in response
to a visual stimulus28 and 0.29 and 0.64 ± 0.26 during a hyper/hypocapnic challenge,29,30 respectively (errors reported where available). MRI‐based
WESOLOWSKI ET AL. 9 of 11experiments using a perfluorocarbon contrast agent and continuous ASL (CASL) measured a value of αtot of 0.4 in rats.
6 However, in all of these
cases measurements were made in the steady state. In this study, a relatively short stimulus duration of 19.2 s was used, which is more relevant
for human imaging studies but may not be long enough to allow a steady state to be reached, and hence may explain the smaller value of αtot mea-
sured (0.16 ± 0.14) for ROICBF. A larger value of αtot was measured (0.45 ± 0.14) for ROICOMMON, albeit for a much smaller active region of tissue.
The literature regarding the coupling of CBF with CBVa is more limited. Perfluorocarbon studies on rats measured the CBVa change due to
steady state hypercapnia and the change in CBF using CASL.6 Reviewing their data, we estimate αa = 0.84. A similar rat study performed by
Kim et al7 measured changes in CBF and CBVa in response to a 15 s somatosensory stimulus using the MOTIVE (MRI with modulation of tissue
and vessel) technique,31 and from these datasets we estimate αa = 1.73. The values for αa obtained in our study (0.65 ± 0.24 and 0.70 ± 0.29) are
at the low end of this range, again perhaps suggesting that a steady state was not achieved using a short stimulus. However, further data are
required to investigate the effects of stimulus, species and anaesthesia differences.
This experiment did not allow a directmeasurement of CBVv changes. In addition, itwas not possible to acquire absolute estimates of CBVtot. There-
fore, the changes in CBVv could only be investigated based on assumptions regarding the partitioning of blood volume by a two‐compartment model
consisting of arterial and venous volume fractions. The arterial volume fraction f a has previously beenmeasured as 0.27,
7 0.29,32 and 0.3–0.37,33 using
a range of techniques, each ofwhich is expected to include a small fraction of the post‐arterial capillary blood volume, whilst the venous volume fraction
f v has beenmeasured as 0.77 using the quantitative BOLD technique.
34 This technique is specifically sensitive to blood vessels containing deoxygenated
blood.Whilst this largely consists of blood within venous vessels, it is also expected to include deoxygenated bloodwithin the capillaries. Therefore, the
arterial and venous compartments defined in this studymightmore accurately be described as the oxygenated and deoxygenated compartments. Impor-
tantly, it is this deoxygenated blood volume that underlies the BOLD response and best reflects the BOLD specific CBF‐CBV coupling. Therefore, based
on the literature values above, f a was assumed to take a value of 0.3. Under this assumption, a non‐significant change inCBVvwas estimated for ROICBF,
whilst a significant change was recorded for ROICOMMON. This would suggest a CBF‐CBVv coupling constant, αv, of around zero for the former and
αv = 0.32 ± 0.14 for the latter. These values bracket the limited range of values of CBF‐CBVv coupling constant given in the literature. In rats a value
of αv of 0.20 was measured using a steady state hypercapnia stimulus,
6 whilst in humans αv was measured as 0.18 for a steady state
hyper/hypocapnic stimulus,10 and0.18/0.31 for low/high intensity visual stimulation.9 However, even in the latter visual stimulus experiments, the stim-
ulus duration was 96 s and therefore significantly longer than that used in our study. In order to examine the effect of short stimuli we can consider
recent work investigating the temporal dynamics of CBVv.
35 In this work CBVv was shown to be delayed with respect to changes in CBF and CBVa.
Given the short duration of our stimulus, it is likely that this would not produce an appreciable increase in CBVv, consistentwith the results from ROICBF.
Furthermore this is consistentwith two photonmicroscopymeasurements that demonstrated aminimal increase in CBVv for a 10 s stimulus, but a larger
and delayed response for a 30 s stimulus.36 Given these findings, the results from ROICOMMON appear to overestimate the change in CBVv.
The inconsistency between the two ROIs considered in this study results from the different voxel selection methods. In the case of ROICBF,
the use of a CBF localizer provides sensitivity to perfusion and hence to exchange at the capillary bed. CBF ROIs have previously been shown to
be more robust than a BOLD‐based localizer.37 In contrast the CBV localizers used in combination with the CBF localizer to define the
ROICOMMON are not specific to any particular vessel scale. Therefore, large vessels in the ROI are likely to be accompanied by small changes in
CBV, whilst small vessels might see larger changes. Whilst the correlation between baseline CBVa and δCBVa is not statistically significant, this
effect likely explains the intersubject variation in the δCBVa time courses (Figures 4 and S1). In addition, it has been observed that changes in CBVv
during activation are spatially heterogenous with both increases and decreases.24 Therefore, selecting for only positive changes in CBV has the
potential to overestimate the fractional change during activation and may explain why a significant change in CBVv was observed for ROICOMMON.5.2 | Limitations of the current study
In this work, ROIs were selected using the activated region defined by the CBF data. However, the use of such functionally defined ROIs can lead to
statistical bias, resulting in an overestimation of changes in CBF.38 Due to the importance of maintaining comfort in human volunteer studies, time
within the scanner was limited. Therefore, it was not possible to acquire an additional CBF dataset to provide an independent definition of the ROI.
A pulsed ASL (PASL) preparation was employed in this study so that the same methodologies could be used for the quantification of both CBF
and CBVa and the effects of transit time could be measured and accounted for. The use of a pseudocontinuous ASL (PCASL) approach to measure
changes in CBF would likely improve the fidelity of such measurements. However, a PCASL preparation cannot be used for CBVa measurements
due to SAR limitations. Therefore, in practice using a PASL preparation for both CBF and CBVa measurements is preferable to maintain the same
labelling efficiency in both experiments.
Absolute quantification of CBVtot was not possible in this study, so we could not measure ΔCBVv. This might be measured by tracking the first
bolus of contrast agent.39 However, the resolution of the data acquired in this study was too coarse to yield an adequate arterial input function.
Absolute CBVtot is reported to be in the range of 3–5 mL/100 g, therefore the results of this study would predict an absolute change in CBVtot
(ΔCBVtot) between 0.18 and 0.3 mL/100 g.
Predictions of αv were based on a two‐compartment model of the vasculature: arterial and venous. It was therefore assumed that the capillary
compartment was distributed between these two compartments. However, it is likely that changes in capillary CBV will have their own character-
istic coupling to CBF and may therefore contribute to an under/overestimation of CBV change in the arterial and venous compartments.
10 of 11 WESOLOWSKI ET AL.Finally, only steady state changes in haemodynamics were studied since the SNR was not sufficient to study dynamic changes. However, it
has been shown that a post‐stimulus undershoot in CBF may contribute to the BOLD post‐stimulus undershoot40 and that changes in CBVv
are delayed with respect to changes in CBVa.
35 These dynamic variations are expected to add to the complexity of the temporal characteristics
of the BOLD response. Repeating this work at higher field might allow the study of these dynamic characteristics, greater knowledge of which
may enable the dynamics of changes in oxygen metabolism to be investigated using extensions to methods such as calibrated BOLD.1,26 | CONCLUSION
In this study, measurements of CBF, CBVa and CBVtot were performed in individual subjects in a single experimental session to assess the coupling
of haemodynamic responses. This information is valuable for furthering our understanding of the BOLD response and for enhancing the accuracy
and reliability of applications that rely on models of the BOLD response, such as calibrated BOLD.
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APPENDIX
The data that underpin the results presented in this work can also be accessed via the Zenodo repository (https://doi.org/10.5281/zenodo.1464828).
